BBR Partners LLC Has $2.79 Million Position in Harrow, Inc. (NASDAQ:HROW)

BBR Partners LLC lifted its holdings in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 181.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 62,000 shares of the company's stock after purchasing an additional 40,000 shares during the period. BBR Partners LLC owned 0.17% of Harrow worth $2,788,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Harrow by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company's stock valued at $24,208,000 after buying an additional 21,253 shares during the last quarter. Oppenheimer & Co. Inc. bought a new position in Harrow in the third quarter valued at about $1,267,000. SG Americas Securities LLC acquired a new stake in Harrow in the third quarter worth about $534,000. Penserra Capital Management LLC bought a new stake in Harrow during the 3rd quarter worth about $1,986,000. Finally, Semanteon Capital Management LP acquired a new position in Harrow during the 3rd quarter valued at about $686,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Stock Up 0.5 %

Shares of NASDAQ:HROW traded up $0.23 during midday trading on Thursday, reaching $42.47. 333,311 shares of the company were exchanged, compared to its average volume of 511,906. The firm has a market cap of $1.51 billion, a PE ratio of -45.18 and a beta of 0.76. Harrow, Inc. has a fifty-two week low of $8.72 and a fifty-two week high of $59.23. The stock has a fifty day simple moving average of $47.76 and a two-hundred day simple moving average of $34.17. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Craig Hallum boosted their price target on shares of Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research note on Friday, October 4th. Lake Street Capital increased their price target on Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a research note on Friday, October 4th. Finally, B. Riley reaffirmed a "buy" rating and set a $50.00 price objective on shares of Harrow in a research note on Thursday, August 29th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.